Intravitreal anti-vascular endothelial growth factor (anti-VEGF) injection has been the first-line therapy for diabetic macular edema (DME), and it has been reported to be effective in improving visual acuity (VA) and reducing central retinal thickness [1]. This evidence concerns the gene VEGFA and diabetic macular edema.